A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.
- 29 Sep 2017 Status changed from planning to not yet recruiting.
- 24 May 2017 New trial record